Updates are available Correction dated 2019-10-21

Article History

First Online: 21 March 2019

Change Date: 21 October 2019

Change Type: Correction

Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Competing interests

: P.C. has received unrestricted research and educational grants from Ipsen, Novartis and Pfizer as Head of the Department of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Sud. P.C. has served as an investigator (principal or coordinator) for clinical trials funded by Antisense, Chiasma, Ipsen,, Italfarmaco, Novartis and Pfizer. P.C. is a member of advisory boards from Ipsen and Novartis. P.C. gave lectures for Ipsen, Novartis and Pfizer. All the fees and honoraria were paid to his institution. S.M. receives investigator-initiated research grants from Ono and Pfizer to his institution. S.M. serves as a consultant for Chiasma, Ionis and Ipsen. A.C. has been a principal investigator of research studies from Ipsen, Lilly, Novartis and Pfizer; has received research grants from Ferring, Ipsen, Lilly, Merck-Serono, Novartis, Novo-Nordisk and Pfizer; has been an occasional consultant for Ipsen, Novartis and Pfizer; and has received fees and honoraria from Ipsen, Novartis and Pfizer. R.P. has been principal investigator of research studies for HRA Pharma and Novartis; has received research grants from Novartis, IBSA, Ipsen, Pfizer and ViroPharma; has been an occasional consultant for Ferring, Ipsen, Italfarmaco, Novartis, Pfizer, and ViroPharma; and received lecture fees and honoraria from Novartis, Pfizer and Shire. A.G. is a consultant for Ipsen, Novartis and Pfizer. L.F.S.G. and A.M.P. declare no competing interests.